CompletedPhase 2NCT01071837
APG101 in Glioblastoma
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Apogenix GmbH
- Principal Investigator
- Wolfgang Wick, MDUniversity Hospital Heidelberg, Dept. of Neurooncology, Germany
- Intervention
- APG101(drug)
- Enrollment
- 84 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2014
Study locations (21)
- Medizinische Universität Graz, Universitätsklinik für Neurologie Landeskrankenhaus Graz, Graz, Austria
- Universitätsklinik für Neurologie, Landeskrankenhaus Innsbruck, Innsbruck, Austria
- Landesnervenklinik Wagner-Jauregg, Innere Medizin mit Neuroonkologie, Linz, Austria
- Allgemeines Krankenhaus der Stadt Wien, Klinische Onkologie, Vienna, Austria
- Charite Universitätsmedizin Berlin, Klinik für Neurochirugie, Berlin, Germany
- Neurologische Universitätsklinik am Knappschaftskrankenhaus, Bochum, Germany
- Neurologische Universitätsklinik Bonn, Schwerpunkt klinische Neuroonkologie, Bonn, Germany
- Universitätsklinik Dresden, Klinik und Poliklinik für Neurochirurgie, Dresden, Germany
- Klinikum Frankfurt/Oder, Klinik für Strahlentherapie/Radioonkologie, Frankfurt (Oder), Germany
- Universitätsklinik Hamburg, Klinik für Neurochirugie, Hamburg, Germany
- Universitätsklinik Heidelberg, Abteilung Neuroonkologie, Heidelberg, Germany
- Universität Leipzig, Klinik für Strahlentherapie, Leipzig, Germany
- Universitätsmedizin Mannheim, Klinik für Neurochirurgie, Mannheim, Germany
- Philipps-Universität Marburg, Klinik für Neurologie, Marburg, Germany
- LMU München, Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Campus Großhadern & Campus Innenstadt, München, Germany
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01071837 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom
- RECRUITINGNANCT07426848OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour PatientsRoyal College of Surgeons, Ireland